NYU Langone

 

Videos
16:00

AACR 2023 Conference Coverage

A Personalized Cancer Vaccine mRNA-4157 + Pembro vs. Pembro in Resected HR-Melanoma: Efficacy & Safety Results From the Randomized, Open-Label Phase 2 mRNA-4157-P201/KEYNOTE-942 Trial

FEATURING Jeffrey Weber
  • 181 views
  • May 9, 2023
07:45

ecancer

Latest Treatments in Esophageal Cancer

FEATURING Costas Bizekis
  • 27 views
  • May 9, 2023
21:26

NYU Langone

Common TKI Toxicity Management in 2L HCC Treatment

FEATURING Jennifer Wu
  • 51 views
  • May 4, 2023
04:53

SGO 2023 Conference Coverage on VuMedi

SGO 2023 Updates on Advanced or Recurrent Endometrial Tumors: NGS Complements Conventional Clinical HER2 Testing

FEATURING Sarah Lee
  • 51 views
  • April 14, 2023
12:04

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Preliminary Efficacy and Correlative Results of the Phase II Trial HCRN GI16-288: Perioperative CV301 Vaccination in Combination With Nivo and Systemic Chemo for Resectable Hepatic-Limited mCRC

FEATURING Kristen Spencer
  • 64 views
  • February 23, 2023
10:29

NYU Langone

FDA Approval of Adagrasib in KRAS G12Cm NSCLC

FEATURING Joshua Sabari
  • 628 views
  • December 16, 2022
  • 5
20:08

NYU Langone

Treatment Questions for Medical Oncologists Treating Melanoma

FEATURING Jeffrey Weber
  • 358 views
  • November 18, 2022
15:30

NYU Langone

TPO-RA Agents in Children With ITP: What to Consider in Terms of Timing and Rationale

FEATURING Kirsty Hillier
  • 25 views
  • October 11, 2022
  • 1
22:51

NYU Langone

Case Presentation on HER2+ Breast Cancer: Adapting Patient Care to a Rapidly Evolving Treatment Landscape

FEATURING Douglas Marks
  • 240 views
  • September 13, 2022
  • 1
17:41

NYU Langone

The Great Debate: Is Neoadjuvant Therapy Really Better Than Adjuvant Therapy in Melanoma?

FEATURING Jeffrey Weber
  • 333 views
  • September 23, 2021
24:32

NYU Langone

Adjuvant and Neoadjuvant Melanoma Dilemmas: Considering Treatment Outcomes With IO and Targeted Therapy Agents

FEATURING Jeffrey Weber
  • 376 views
  • May 20, 2021
  • 1
14:08

NYU Langone

2020 CheckMate 238 Update on IO in Advanced Stage Melanoma: Did Nivo Show Sustained Superior Patient Benefit vs. Ipi in High-Risk Resected Disease?

FEATURING Jeffrey Weber
  • 1,136 views
  • November 9, 2020
  • 2